iso-PPADS tetrasodium saltP2 purinoceptors antagonist, specific CAS# 207572-67-6 |
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- Dexrazoxane HCl (ICRF-187, ADR-529)
Catalog No.:BCC1087
CAS No.:149003-01-0
- Doxorubicin (Adriamycin) HCl
Catalog No.:BCC1117
CAS No.:25316-40-9
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 207572-67-6 | SDF | Download SDF |
PubChem ID | 135458049 | Appearance | Powder |
Formula | C14H10N3Na4O12PS2 | M.Wt | 599.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | tetrasodium;2-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonatooxymethyl)pyridin-2-yl]diazenyl]benzene-1,4-disulfonate | ||
SMILES | CC1=C(C(=C(C(=N1)N=NC2=C(C=CC(=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])COP(=O)([O-])[O-])C=O)O.[Na+].[Na+].[Na+].[Na+] | ||
Standard InChIKey | SDCXIPVOUDBGDK-UHFFFAOYSA-J | ||
Standard InChI | InChI=1S/C14H14N3O12PS2.4Na/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-4-8(31(23,24)25)2-3-12(11)32(26,27)28;;;;/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28);;;;/q;4*+1/p-4 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | P2X-purinoceptor antagonist (pKi = 6.5) with similar activity to PPADS. |
iso-PPADS tetrasodium salt Dilution Calculator
iso-PPADS tetrasodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6686 mL | 8.3431 mL | 16.6861 mL | 33.3723 mL | 41.7153 mL |
5 mM | 0.3337 mL | 1.6686 mL | 3.3372 mL | 6.6745 mL | 8.3431 mL |
10 mM | 0.1669 mL | 0.8343 mL | 1.6686 mL | 3.3372 mL | 4.1715 mL |
50 mM | 0.0334 mL | 0.1669 mL | 0.3337 mL | 0.6674 mL | 0.8343 mL |
100 mM | 0.0167 mL | 0.0834 mL | 0.1669 mL | 0.3337 mL | 0.4172 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Iso-PPADS tetrasodium salt is a specific P2 purinoceptors antagonist [3].
P2 purinoceptors mediate the actions of adenosine 5'-tri- phosphate (ATP) on many physiological systems including most vascular and visceral smooth muscles and certain neur- ones in the peripheral and central nervous systems
IsoPPADS (10 uM) depressed alpha, beta-Me-ATP-evoked depolarizations but did not alter depolarizations evoked by UTP. So it is concluded that IsoPPADS is antagonist at P2x-purinoceptor but not at the receptor that mediate UTP-evoked depolarization of the rat superior cervical ganglion [1]. In functional studies, iso-PPADS identified two populations of [3H]alpha,beta-meATP binding sites, 26.4% of these having low affinity (pKi of 4.4 +/- 0.2), and 73.6% having high affinity (pKi of 6.5 +/- 0.02) for iso-PPADS [2]. Iso-PPADS (1 X 10-6 -1 X 10-5 M) produced a concentration-related depression in the maxima of the concentration-effect curves to alpha,beta-methylene ATP. The antagonistic effect of iso-PPADS (1 x 10-5 M) was partially attenuated by suramin (1 x 10-4 M) and this interaction reflects a slow dissociation of iso-PPADS from the receptor with which suramin and alpha, beta-methylene ATP interact [3].
Reference:
[1]. Connolly GP. Differentiation by pyridoxal 5-phosphate, PPADS and isoPPADS between responses mediated by UTP and those evoked by α, β-methylene-ATP on rat sympathetic ganglia. Br J Pharmacol, 1995, 114(3): 727-731.
[2]. Khakh BS, Michel A, Humphrey PP. Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens. Eur J Pharmacol, 1994, 263(3): 301-309.
[3]. Trezise DJ, Kennedy I, Humphrey PP. The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by α,β-methylene adenosine 5'-triphosphate. Br J Pharmacol, 1994, 112(1): 282-288.
- Pirlindole mesylate
Catalog No.:BCC6764
CAS No.:207572-66-5
- (±)-1-(1,2-Diphenylethyl)piperidine maleate
Catalog No.:BCC6619
CAS No.:207461-99-2
- BTCP maleate
Catalog No.:BCC6753
CAS No.:207455-25-2
- L-693,403 maleate
Catalog No.:BCC5657
CAS No.:207455-21-8
- N-MPPP Hydrochloride
Catalog No.:BCC5672
CAS No.:207452-97-9
- Arteannuin N
Catalog No.:BCN4907
CAS No.:207446-92-2
- Arteannuin M
Catalog No.:BCN4906
CAS No.:207446-90-0
- Arteannuin L
Catalog No.:BCN4905
CAS No.:207446-89-7
- MR 16728 hydrochloride
Catalog No.:BCC6684
CAS No.:207403-36-9
- 3-Bromocytisine
Catalog No.:BCC7705
CAS No.:207390-14-5
- Dihydrosinapylalcohol
Catalog No.:BCN6542
CAS No.:20736-25-8
- Saikosaponin A
Catalog No.:BCN1086
CAS No.:20736-09-8
- SB 203186 hydrochloride
Catalog No.:BCC5673
CAS No.:207572-69-8
- H-Phe(4-NO2)-OH.H2O
Catalog No.:BCC3273
CAS No.:207591-86-4
- TPT-260 Dihydrochloride
Catalog No.:BCC5172
CAS No.:2076-91-7
- HS 014
Catalog No.:BCC5819
CAS No.:207678-81-7
- 5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)
Catalog No.:BCC4583
CAS No.:207679-81-0
- 1,7-Bis(4-hydroxyphenyl)-3-hydroxy-1,3-heptadien-5-one
Catalog No.:BCN6470
CAS No.:207792-17-4
- Propofol
Catalog No.:BCC9130
CAS No.:2078-54-8
- Isobavachalcone
Catalog No.:BCN5415
CAS No.:20784-50-3
- 4'-O-Methylbroussochalcone B
Catalog No.:BCN4908
CAS No.:20784-60-5
- Hemokinin 1 (mouse)
Catalog No.:BCC5774
CAS No.:208041-90-1
- Z-Ser(Bzl)-OH
Catalog No.:BCC2742
CAS No.:20806-43-3
- Strictosidine
Catalog No.:BCN2641
CAS No.:20824-29-7
Conventional high-performance liquid chromatography versus derivative spectrophotometry for the determination of 1,3,6-pyrenetrisulfonic acid trisodium salt and 1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt in the color additive D&C Green No. 8 (Pyranine).[Pubmed:24315677]
J Chromatogr A. 2014 Jan 10;1324:238-41.
Specifications in the U.S. Code of Federal Regulations for the color additive D&C Green No. 8 (Colour Index No. 59040) limit the levels of the subsidiary colors 1,3,6-pyrenetrisulfonic acid trisodium salt (P3S) and 1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt (P4S). The present paper describes a comparative study of two possible methods to replace the currently used multi-step TLC/spectrophotometry method of separating and quantifying the minor components P3S and P4S in G8. One of the new approaches uses conventional high-performance liquid chromatography (HPLC) and the other, derivative spectrophotometry. While the derivative spectrophotometric method was shown to be inadequate for the analysis of minor components overwhelmed by components of much higher concentration, the HPLC method was proven highly effective. The closely related, very polar compounds P3S and P4S were separated by the new HPLC method in less than 4 min using a conventional HPLC instrument. P3S and P4S were quantified by using five-point calibration curves with data points that ranged from 0.45 to 7.63% and from 0.13 to 1.82%, by weight, for P3S and P4S, respectively. The HPLC method was applied to the analysis of test portions from 20 batches of D&C Green No. 8 submitted to the U.S. Food and Drug Administration for certification.
Intermolecular interaction of nickel (ii) phthalocyanine tetrasulfonic acid tetrasodium salt with bovine serum albumin: A multi-technique study.[Pubmed:27831822]
Nucleosides Nucleotides Nucleic Acids. 2017 Feb;36(2):122-138.
The interaction of nickel (II) phthalocyanine tetrasulfonic acid tetrasodium salt with bovine serum albumin (BSA) has been investigated by combination of fluorescence, UV-vis absorption, Fourier transform infrared (FT-IR), and circular dichorism (CD) spectroscopies as well as through molecular docking. Fluorescence quenching and absorption spectra were investigated as a mean for estimating the binding parameters. Analysis of fluorescence quenching data at different temperatures was performed in order to specify the thermodynamics parameters for interactions of phthalocyanine complex with BSA. According to experimental data it was suggested that phthalocyanine had a significant binding affinity to BSA and the process was entropy driven. Based on the results of molecular docking it was indicated that the main active binding site for this phthalocyanine complex is site I in subdomain IIA of BSA. The results provide useful information for understanding the binding mechanism of anticancer drug-albumin and gives insight into the biological activity and metabolism of the drug in blood.
Meso-tetrakis(p-sulfonatophenyl)N-confused porphyrin tetrasodium salt: a potential sensitizer for photodynamic therapy.[Pubmed:22582931]
J Med Chem. 2012 Jun 14;55(11):5110-20.
A water-soluble derivative of N-confused porphyrin (NCP) was synthesized, and the photodynamic therapeutic (PDT) application was investigated by photophysical and in vitro studies. High singlet oxygen quantum yield in water at longer wavelength and promising IC(50) values in a panel of cancer cell lines ensure the potential candidacy of the sensitizer as a PDT drug. Reactive oxygen species (ROS) generation on PDT in MDA-MB 231 cells and the apoptotic pathway of cell death was illustrated using different techniques.
NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-car bonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.[Pubmed:19815812]
J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.
The G protein-coupled P2Y(11) receptor is involved in immune system modulation. In-depth physiological evaluation is hampered, however, by a lack of selective and potent ligands. By screening a library of sulfonic and phosphonic acid derivatives at P2Y(11) receptors recombinantly expressed in human 1321N1 astrocytoma cells (calcium and cAMP assays), the selective non-nucleotide P2Y(11) agonist NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)carb onylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] was identified. NF546 had a pEC(50) of 6.27 and is relatively selective for P2Y(11) over P2Y(1), P2Y(2), P2Y(4), P2Y(6), P2Y(12), P2X(1), P2X(2), and P2X(2)-X(3). Adenosine-5'-O-(3-thio)triphosphate (ATPgammaS), a nonhydrolyzable analog of the physiological P2Y(11) agonist ATP, and NF546 use a common binding site as suggested by molecular modeling studies and their competitive behavior toward the nanomolar potency antagonist NF340 [4,4'-(carbonylbis(imino-3,1-(4-methyl-phenylene)carbonylimino))bis(naphthalene-2 ,6-disulfonic acid) tetrasodium salt] in Schild analysis. The pA(2) of NF340 was 8.02 against ATPgammaS and 8.04 against NF546 (calcium assays). NF546 was further tested for P2Y(11)-mediated effects in monocyte-derived dendritic cells. Similarly to ATPgammaS, NF546 led to thrombospondin-1 secretion and inhibition of lipopolysaccharide-stimulated interleukin-12 release, whereas NF340 inhibited these effects. Further, for the first time, it was shown that ATPgammaS or NF546 stimulation promotes interleukin 8 (IL-8) release from dendritic cells, which could be inhibited by NF340. In conclusion, we have described the first selective, non-nucleotide agonist NF546 for P2Y(11) receptors in both recombinant and physiological expression systems and could show a P2Y(11)-stimulated IL-8 release, further supporting the immunomodulatory role of P2Y(11) receptors.
Differentiation by pyridoxal 5-phosphate, PPADS and IsoPPADS between responses mediated by UTP and those evoked by alpha, beta-methylene-ATP on rat sympathetic ganglia.[Pubmed:7735699]
Br J Pharmacol. 1995 Feb;114(3):727-31.
1. The effect of pyridoxal 5-phosphate, and the 2',4' and 2',5'-disulphonic acid isomers of 6-azophenylpyridoxal 5-phosphate (PPADS and IsoPPADS respectively) on depolarization of the rat superior cervical ganglion evoked by alpha, beta-methylene-adenosine 5'-triphosphate (alpha, beta-Me-ATP) and uridine 5'-triphosphate (UTP) were determined by a grease-gap recording technique. 2. Pyridoxal 5-phosphate (10-100 microM) and PPADS (10-100 microM) enhanced UTP- and depressed alpha, beta-Me-ATP-evoked depolarizations but did not significantly alter depolarizations evoked by potassium or hyperpolarizations evoked by adenosine. IsoPPADS (10 microM) depressed alpha, beta-Me-ATP-evoked depolarizations but did not alter depolarizations evoked by UTP. Depolarizations evoked by muscarine were depressed by IsoPPADS but not by pyridoxal 5-phosphate. 3. It is concluded that pyridoxal 5-phosphate, PPADS and IsoPPADS are antagonists at P2x-purinoceptors but not at the receptors that mediate UTP-evoked depolarization of the rat superior cervical ganglion. These observations substantiate the recent proposal that the rat superior cervical ganglia possess distinct receptors for purine and pyrimidine 5'-nucleotides, i.c. P2x-purinoceptors and pyrimidinoceptors respectively.
Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens.[Pubmed:7843268]
Eur J Pharmacol. 1994 Oct 3;263(3):301-9.
In functional studies pyridoxalphosphate-6-azophenyl-2',5'-disulphonic acid (iso-PPADS), suramin, GR200282 (4,4'-[carbonyl-bis(imino-3- benzoylimino)]-bis[5-hydroxy-naphthalene-2,7-disulfonic acid] tetrapotassium salt), cibacron blue, trypan blue and congo red, each produced specific antagonism of the contractile responses of isolated rat vas deferens, induced by alpha,beta-methylene ATP (alpha,beta-meATP), with antagonist pKB estimates of 6.6 +/- 0.3, 5.5 +/- 0.2, 5.1 +/- 0.3, 5.8 +/- 0.2, 4.7 +/- 0.2 and 4.6 +/- 0.2, respectively. In radioligand binding studies, iso-PPADS, suramin, cibacron blue, GR200282, trypan blue and congo red competed for the high affinity [3H]alpha,beta-meATP binding sites in rat vas deferens membranes with pKi estimates of 5.6 +/- 0.04, 5.5 +/- 0.08, 5.6 +/- 0.15, 5.6 +/- 0.04, 4.3 +/- 0.06 and 4.9 +/- 0.10, respectively. Comparison of pKB and pKi estimates revealed a good agreement between the two approaches for estimating measures of affinity for the putative antagonists, except in the case of iso-PPADS. However, we found that two populations of [3H]alpha,beta-meATP binding sites can be identified by iso-PPADS, 26.4% of these having low affinity (pKi of 4.4 +/- 0.2), and 73.6% having high affinity (pKi of 6.5 +/- 0.02) for iso-PPADS. The pKi of 6.5 obtained at the high affinity sites identified by iso-PPADS was close to the equivalent pKB value of 6.6 from functional studies. These studies therefore show a good agreement between pKB and pKi estimates for several antagonists, and suggest that the high affinity binding sites labelled with [3H]alpha,beta-meATP in rat vas deferens represents binding to functional P2X purinoceptors.
The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.[Pubmed:8032652]
Br J Pharmacol. 1994 May;112(1):282-8.
1. We have previously found that the P2x-purinoceptor agonist, alpha, beta-methylene adenosine 5'-triphosphate (alpha, beta-methylene ATP), depolarizes the rat cervical vagus nerve, measured with a 'grease-gap' extracellular recording technique. This effect was attenuated by the P2 purinoceptor antagonist, suramin. In the present study we have investigated in more detail the antagonism produced by suramin and have also investigated the actions of two other putative P2 purinoceptor antagonists, cibacron blue and pyridoxal-phosphate-6-azophenyl-2', 5'-disulphonic acid (iso-PPADS). Furthermore, we have studied the interactions between suramin and cibacron blue or iso-PPADS in an attempt to determine whether these antagonists act at a common receptor site. 2. Suramin (1 x 10(-5)-1 x 10(-4) M) produced reversible, concentration-related rightward displacements of the concentration-effect curve to alpha, beta-methylene ATP. Schild analysis of this antagonism yielded a pA2 value of 5.90 with a slope value of 0.47. 3. Cibacron blue (3 x 10(-5)-1 x 10(-4) M) also antagonized depolarizations induced by alpha, beta-methylene ATP. The antagonistic effects of cibacron blue were slow to reach equilibrium but could be readily reversed on washout. At low concentrations for antagonism, cibacron blue (1 x 10(-5) M and 3 x 10(-5) M) produced enhancement of the maximal response to alpha, beta-methylene ATP. At the highest concentration tested (1 x 10(-4) M) the concentration-effect curve to alpha, beta-methylene ATP was shifted to the right in a parallel manner, yielding a pKB estimate of 4.96. 4. Iso-PPADS (1 X 10-6 1 X 10-5- M) produced a concentration-related depression in the maxima ofthe concentration-effect curves to alpha,beta-methylene ATP. Analysis of these data by a double reciprocal plot yielded a pKB estimate of 6.02. This profile of insurmountable antagonism could not be attributed to irreversible binding of iso-PPADS to the receptor since the effect of iso-PPADS could be reversed on washing, albeit slowly.5. In the presence of suramin (1 x 10-4 M), cibacron blue (1 x 10-4 M) produced no further rightward displacement of the alpha,beta-methylene ATP concentration-effect curve. The mean agonist concentration ratios in the presence of suramin or cibacron blue alone (11.7 and 10.3, respectively) were not significantly different from the mean concentration-ratio in the presence of both antagonists (11.8). This finding suggests that high concentrations of alpha,beta-methylene ATP activate a receptor population which is resistant to blockade by either antagonist.6. The antagonistic effect of iso-PPADS (1 x 10-5 M) was partially attenuated by suramin (1I x 10-4 M).It is possible that this interaction reflects a slow dissociation of iso-PPADS from the receptor with which suramin and alpha,beta-methylene ATP interact.7. Suramin, cibacron blue or iso-PPADS had no marked effect on depolarization produced by 5-hydroxytryptamine (5-HT, 1 x 10-7-3 x 10-5 M), indicating their specificity in antagonizing responses to alpha, beta-methylene ATP.8. Responses to alpha,beta-methylene ATP were not antagonized by 8-para-sulphophenyltheophylline (3 x 10-5M), ondansetron (1 x 10-7 M), bicuculline (1 x I0-5 M), phentolamine (1 X 10-6 M) or hexamethonium(1 X 10-4 M), which are antagonists at P1-purinoceptors, 5-HT3 receptors, GABAA receptors, a-adrenoceptors and nicotinic cholinoceptors, respectively, thereby excluding the involvement of these receptors.Indomethacin (3 X 10-6 M) had no effect on responses to alpha,beta-methylene ATP.9. The results obtained with three purinoceptor antagonists confirm and extend our original supposition that alpha,beta-methylene ATP-induced depolarization of the rat vagus nerve is mediated predominantly via P2 purinoceptors, thought to be of the P2,X subtype. The finding that responses induced by high concentrations of agonist were resistant to blockade by suramin and cibacron blue, but could be attenuated by iso-PPADS, adds further weight to our speculation that the purinoceptor population in the rat vagus nerve is heterogeneous.